The global burden of human immunodeficiency virus (HIV) remains a significant challenge to public health worldwide. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 1.3 million new HIV infections were reported in 2023, culminating in an estimated 39.9 million individuals living with HIV by the end of the year. Additionally, 630,000 deaths were attributed to HIV-related illnesses globally in the same year [1]. A considerable proportion of HIV-related morbidity and mortality is driven by opportunistic coinfections, which exploit the compromised immune systems of HIV-positive individuals [2–4]. Therefore, early and accurate identification of coinfecting pathogens is critical for optimizing antimicrobial therapy and improving clinical outcomes [5].

Conventional microbiological tests (CMTs), including culture, parasitological microscopy, quantitative polymerase chain reaction (qPCR), serological tests, and biochemical assays, remain the cornerstone of diagnostic approaches for HIV-related coinfections. However, these methodologies have significant limitations. For example, microbial isolation through culture often requires prolonged incubation periods and demonstrates low sensitivity, particularly for slow-growing or unculturable pathogens such as Mycobacterium tuberculosis (MTB) and Pneumocystis jirovecii (P. jirovecii), both of which are common in HIV coinfections [6, 7]. Similarly, the performance of qPCR is constrained by its reliance on prior knowledge of target pathogens, limiting its utility for detecting emerging, rare, or unexpected pathogens. On the other hand, serological tests are prone to false-negative results in HIV patients due to weakened immune responses. Furthermore, the inability of CMTs to reliably detect mixed infections or atypical pathogens frequently delays appropriate therapeutic interventions.

In recent years, metagenomic next-generation sequencing (mNGS) has emerged as a transformative diagnostic tool in clinical laboratories. Unlike CMTs, mNGS is culture-independent, unbiased, high-throughput, and capable of detecting a broader range of pathogens with higher accuracy and speed. This technology has shown particular promise in diagnosing HIV-related coinfections, including pulmonary and central nervous system (CNS) infections. Nevertheless, despite growing evidence supporting the utility of mNGS, comparative analyses of its diagnostic performance relative to CMTs across diverse infection types in HIV patients remain limited.

This study aims to evaluate the diagnostic utility of mNGS for coinfections in HIV-positive individuals and to explore its implications for personalized therapy and clinical decision-making.

Owing to the immunodeficiency associated with HIV infection, patients with HIV are more susceptible to a wide range of infections. HIV/AIDS not only facilitates the occurrence of diseases caused by opportunistic pathogens that seldom infect healthy individuals but also substantially exacerbates the clinical manifestations of other pathogens. Common coinfections include tuberculosis, fungal infections, and P. jirovecii pneumonia. For example, tuberculosis is more likely to cause active disease in individuals with HIV [4, 9], whereas coinfection with HBV more rapidly leads to liver damage, significantly increasing the risk of mortality [10, 11]. The viral envelope glycoproteins of HIV indirectly promote the occurrence and progression of these coinfections by modulating viral replication efficiency and facilitating immune evasion [12].

These coinfections substantially increase morbidity and mortality among HIV-infected patients. Therefore, it is not surprising that coinfections in HIV/AIDS patients should receive more attention from the global health community. Although CMTs based primarily on culture remain the gold standard for identifying pathogenic microorganisms, the mycological culture process is cumbersome, time-consuming, and has a low positive detection rate. For example, the culture of certain fungi may take several weeks, and many pathogens cannot be cultured at all. In this study, among seven patients ultimately diagnosed with fungal infections, only two yielded positive culture results. Although the GM or G test results were positive in these cases, the results suggest the possibility of fungal infection, but cannot identify specific pathogens. This diagnostic uncertainty may lead to empirical antifungal therapy, which carries a degree of therapeutic uncertainty.

mNGS offers a rapid and comprehensive pathogen detection method for infectious diseases. The adoption of mNGS technologies in clinical diagnostics is increasing, and several studies have reported the application of mNGS in central neurological infections of HIV patients, including tuberculosis meningitis and neurosyphilis [13–15], as well as in sepsis and pneumocystis [6, 16]. However, research comprehensively evaluating the suitability of mNGS across diverse types of coinfections in HIV-infected patients remains limited. In this study, we retrospectively analyzed the diagnostic efficacy of the mNGS method on the basis of different types of samples to evaluate its diagnostic value for coinfections in HIV-positive patients. These results indicate that mNGS has broader pathogen coverage than CMTs do, suggesting that mNGS has greater diagnostic sensitivity and accuracy than CMTs do, underscoring its potential clinical utility in identifying coinfections in HIV-infected individuals.

Our study was limited to a single-center design with a relatively small sample size, which may have introduced potential selection bias. Although mNGS has been accepted and applied in HIV-infected patients, there are currently no standardized guidelines for interpreting test reports in this population. In cases in which mNGS detects multiple potential pathogenic microorganisms, low-abundance viruses (such as circovirus, Epstein-Barr virus, and cytomegalovirus) and commonly colonizing bacteria (such as Staphylococcus epidermidis) are often subjectively classified as nonpathogenic. However, the interpretation criteria in our study were based on previously established evidence from similar sequencing platforms and sample populations. In practice, a more comprehensive approach should be adopted, taking into account the unique susceptibility of HIV-infected patients to opportunistic infections, to enable more accurate clinical judgments. Finally, while our study highlights the positive impact of mNGS on clinical decision-making, the economic burden of routine mNGS implementation in clinical practice must be carefully evaluated. The high cost of mNGS may limit its accessibility, particularly in resource-limited settings where the HIV prevalence is highest. Future studies are needed to address these limitations.

In addition to mNGS, several novel pathogen nucleic acid detection methods have been developed. For example, the target-navigated CBT-Cys “Stapling” technique, coupled with the CRISPR/Cas12a amplification technique, integrates enzyme-free ligation with CRISPR/Cas12a-mediated cleavage amplification. This approach uses rolling circle amplification (RCA) to generate abundant target amplicons, which subsequently trigger CRISPR-mediated signal amplification, resulting in significantly increased detection sensitivity. This dual amplification strategy is particularly suitable for the sensitive detection of low-abundance pathogen nucleic acids, thereby facilitating early diagnosis and infection monitoring [17]. Therefore, with ongoing technological advancements, detection methods for coinfections in HIV patients are expected to become increasingly sophisticated and effective in the future.